Analyzing survival rates and treatment costs for pancreatic cancer patients
Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan
National Cancer Center, Korea · NCT04984174
This study looks at how well treatments for pancreatic cancer work and how much they cost to help patients and healthcare providers make better choices.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 54000 (estimated) |
| Sex | All |
| Sponsor | National Cancer Center, Korea (other gov) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Goyang-si, Gyeonggi-do) |
| Trial ID | NCT04984174 on ClinicalTrials.gov |
What this trial studies
This study utilizes the National Health Insurance Service database and the K-PaC registry to analyze the survival rates and treatment costs associated with pancreatic cancer over the past 15 years. It focuses on the economic impact and effectiveness of treatments, particularly the use of liposomal irinotecan as a second-line therapy. By examining patient records and billing data from 2005 to 2020, the study aims to provide insights that could influence healthcare policy and reimbursement decisions for pancreatic cancer treatments. The findings may help in understanding the cost-effectiveness of current treatment regimens and their impact on patient survival.
Who should consider this trial
Good fit: Ideal candidates for this study are pancreatic cancer patients who have medical records and billing data from 2005 to 2020.
Not a fit: Patients who have undergone surgery for pancreatic cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable data to improve treatment strategies and healthcare policies for pancreatic cancer patients.
How similar studies have performed: Other studies have shown success in analyzing treatment costs and survival rates in cancer, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pancreatic cancer patients with records of medical users and billing data from 2005 to 2020 Exclusion Criteria: * Patients who underwent surgery for pancreatic cancer
Where this trial is running
Goyang-si, Gyeonggi-do
- NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu, — Goyang-si, Gyeonggi-do, Korea, Republic of (RECRUITING)
Study contacts
- Principal investigator: Sangmyung Woo, MD — Nation Cancer Center, Republic of Korea
- Study coordinator: Sangmyung Woo, MD
- Email: wsm@ncc.re.kr
- Phone: 82 31 920 1733
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pancreatic Cancer, pancreatic cancer